Needham Maintains Buy on Cytokinetics, Raises Price Target to $112
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $102 to $112.
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $102 to $112.